{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:36:42Z","timestamp":1768585002975,"version":"3.49.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,9,1]]},"DOI":"10.1093\/jac\/dkh390","type":"journal-article","created":{"date-parts":[[2004,8,5]],"date-time":"2004-08-05T00:16:39Z","timestamp":1091664999000},"page":"654-660","source":"Crossref","is-referenced-by-count":20,"title":["Therapeutic efficacy of the magainin analogue MSI-78 in different intra-abdominal sepsis rat models"],"prefix":"10.1093","volume":"54","author":[{"given":"Andrea","family":"Giacometti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Ghiselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Cirioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Mocchegiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"D'Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorenza","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Sisti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Kamysz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Naldoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"\u0141ukasiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Scalise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,9]]},"reference":[{"key":"key\n\t\t\t\t20171010160019_R1","doi-asserted-by":"crossref","unstructured":"Wheeler, A. P. & Bernard, G. R. (1999). Treating patients with severe sepsis. New England Journal of Medicine340, 207\u201314.","DOI":"10.1056\/NEJM199901213400307"},{"key":"key\n\t\t\t\t20171010160019_R2","doi-asserted-by":"crossref","unstructured":"Brun-Buisson, C., Doyan, F., Carlet, J. et al. (1995). Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. Journal of the American Medical Association274, 968\u201374.","DOI":"10.1001\/jama.1995.03530120060042"},{"key":"key\n\t\t\t\t20171010160019_R3","doi-asserted-by":"crossref","unstructured":"Wenzel, R. P., Pinsky, M. R., Ulevitch, R. J. et al. (1996). Current understanding of sepsis. Clinical Infectious Diseases22, 407\u201313.","DOI":"10.1093\/clinids\/22.3.407"},{"key":"key\n\t\t\t\t20171010160019_R4","doi-asserted-by":"crossref","unstructured":"Ruiz-Perez, B., Cisneros, R. L., Matsumoto, T. et al. (2003). Protection against lethal intra-abdominal sepsis by 1-(3-dimethylaminopropyl)-3-ethylurea. Journal of Infectious Diseases188, 378\u201387.","DOI":"10.1086\/376556"},{"key":"key\n\t\t\t\t20171010160019_R5","doi-asserted-by":"crossref","unstructured":"Hack, C. E., Aarden, L. A. & Thijs, L. G. (1997). Role of cytokines in sepsis. Advances in Immunology66, 101\u201395.","DOI":"10.1016\/S0065-2776(08)60597-0"},{"key":"key\n\t\t\t\t20171010160019_R6","doi-asserted-by":"crossref","unstructured":"Bone, R. C. (1991). Pathophysiology of sepsis. Annals of Internal Medicine115, 457\u201369.","DOI":"10.7326\/0003-4819-115-6-457"},{"key":"key\n\t\t\t\t20171010160019_R7","doi-asserted-by":"crossref","unstructured":"Lamping, N., Dettmer, R., Schr\u00f6der, N. W. J. et al. (1998). LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. Journal of Clinical Investigation101, 2065\u201371.","DOI":"10.1172\/JCI2338"},{"key":"key\n\t\t\t\t20171010160019_R8","doi-asserted-by":"crossref","unstructured":"Glauser, M. P., Zanetti, G., Baumgartner, J. D. et al. (1991). Septic shock: pathogenesis. Lancet338, 732\u20136.","DOI":"10.1016\/0140-6736(91)91452-Z"},{"key":"key\n\t\t\t\t20171010160019_R9","doi-asserted-by":"crossref","unstructured":"Cirioni, O., Giacometti, A., Ghiselli, R. et al. (2002). Single-dose intraperitoneal magainins improve survival in a Gram-negative-pathogens septic shock rat model. Antimicrobial Agents and Chemotherapy46, 101\u20134.","DOI":"10.1128\/AAC.46.1.101-104.2002"},{"key":"key\n\t\t\t\t20171010160019_R10","doi-asserted-by":"crossref","unstructured":"Jourdain, M., Carrette, O., Tournoys, A. et al. (1997). Effects of inter-\u03b1-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation. American Journal of Respiratory and Critical Care Medicine156, 1825\u201333.","DOI":"10.1164\/ajrccm.156.6.9611100"},{"key":"key\n\t\t\t\t20171010160019_R11","doi-asserted-by":"crossref","unstructured":"Iwagaki, A., Porro, M. & Pollack, M. (2000). Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14. Infection and Immunity68, 1655\u201363.","DOI":"10.1128\/IAI.68.3.1655-1663.2000"},{"key":"key\n\t\t\t\t20171010160019_R12","doi-asserted-by":"crossref","unstructured":"Parker, S. J. & Watkins, P. E. (2000). Experimental models of Gram-negative sepsis. British Journal of Surgery88, 22\u201330.","DOI":"10.1046\/j.1365-2168.2001.01632.x"},{"key":"key\n\t\t\t\t20171010160019_R13","doi-asserted-by":"crossref","unstructured":"Onderdonk, A. B., Weinstein, W. M., Sullivan, N. M. et al. (1974). Experimental intraabdominal abscesses in rats: quantitative bacteriology of infected animals. Infection and Immunity10, 1256\u20139.","DOI":"10.1128\/IAI.10.6.1256-1259.1974"},{"key":"key\n\t\t\t\t20171010160019_R14","doi-asserted-by":"crossref","unstructured":"Hardaway, R. M. (2000). A review of septic shock. American Surgeon66, 22\u20139.","DOI":"10.1177\/000313480006600105"},{"key":"key\n\t\t\t\t20171010160019_R15","doi-asserted-by":"crossref","unstructured":"Mira, J. P., Cariou, A., Grall, F. et al. (1999). Association of TNF2, a TNF\u03b1 promoter polymorphism, with septic shock susceptibility and mortality. Journal of the American Medical Association282, 561\u20138.","DOI":"10.1001\/jama.282.6.561"},{"key":"key\n\t\t\t\t20171010160019_R16","doi-asserted-by":"crossref","unstructured":"Hancock, R. E. W. (2001). Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infectious Diseases1, 156\u201364.","DOI":"10.1016\/S1473-3099(01)00092-5"},{"key":"key\n\t\t\t\t20171010160019_R17","doi-asserted-by":"crossref","unstructured":"Cannon, M. (1987). A family of wound healers. Nature328, 478.","DOI":"10.1038\/328478a0"},{"key":"key\n\t\t\t\t20171010160019_R18","doi-asserted-by":"crossref","unstructured":"Hancock, R. E. W. & Scott, M. G. (2000). The role of antimicrobial peptides in animal defenses. Proceedings of the National Academy of Sciences USA97, 8856\u201361.","DOI":"10.1073\/pnas.97.16.8856"},{"key":"key\n\t\t\t\t20171010160019_R19","doi-asserted-by":"crossref","unstructured":"Gough, M., Hancock, R. E. W. & Kelly, N. M. (1996). Antiendotoxin activity of cationic peptide antimicrobial agents. Infection and Immunity64, 4922\u20137.","DOI":"10.1128\/IAI.64.12.4922-4927.1996"},{"key":"key\n\t\t\t\t20171010160019_R20","doi-asserted-by":"crossref","unstructured":"Giacometti, A., Cirioni, O., Ghiselli, R. et al. (2003). Administration of protegrin peptide IB-367 to prevent endotoxin-induced mortality in bile duct-ligated rats. Gut52, 874\u20138.","DOI":"10.1136\/gut.52.6.874"},{"key":"key\n\t\t\t\t20171010160019_R21","doi-asserted-by":"crossref","unstructured":"Zasloff, M. (1987). Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proceedings of the National Academy of Sciences USA84, 5449\u201353.","DOI":"10.1073\/pnas.84.15.5449"},{"key":"key\n\t\t\t\t20171010160019_R22","doi-asserted-by":"crossref","unstructured":"Ge, Y., MacDonald, D., Henry, M. M. et al. (1999). In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagnostic Microbiology and Infectious Disease35, 45\u201353.","DOI":"10.1016\/S0732-8893(99)00056-5"},{"key":"key\n\t\t\t\t20171010160019_R23","doi-asserted-by":"crossref","unstructured":"Ge, Y., MacDonald, D., Holroyd, K. J. et al. (1999). In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrobial Agents and Chemotherapy43, 782\u20138.","DOI":"10.1128\/AAC.43.4.782"},{"key":"key\n\t\t\t\t20171010160019_R24","doi-asserted-by":"crossref","unstructured":"Fuchs, P. C., Barry, A. L. & Brown, S. D. (1998). In vitro antimicrobial activity of MSI-78, a magainin analog. Antimicrobial Agents and Chemotherapy42, 1213\u20136.","DOI":"10.1128\/AAC.42.5.1213"},{"key":"key\n\t\t\t\t20171010160019_R25","doi-asserted-by":"crossref","unstructured":"Fields, G. B. & Noble, R. L. (1990). Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. International Journal of Peptide and Protein Research35, 161\u2013214.","DOI":"10.1111\/j.1399-3011.1990.tb00939.x"},{"key":"key\n\t\t\t\t20171010160019_R26","doi-asserted-by":"crossref","unstructured":"Christensen, T. (1979). Qualitative test for monitoring coupling completeness in solid phase peptide synthesis using chloranil. Acta Chemica Scandinavica. Series B. Organic Chemistry and Biochemistry33, 763\u201376.","DOI":"10.3891\/acta.chem.scand.33b-0763"},{"key":"key\n\t\t\t\t20171010160019_R27","unstructured":"National Committee for Clinical Laboratory Standards. (2001). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically\u2014Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA."},{"key":"key\n\t\t\t\t20171010160019_R28","doi-asserted-by":"crossref","unstructured":"Kumar, A. & Anel, R. L. (2001). Experimental and emerging therapies for sepsis and septic shock. Expert Opinion on Investigational Drugs10, 1471\u201385.","DOI":"10.1517\/13543784.10.8.1471"},{"key":"key\n\t\t\t\t20171010160019_R29","doi-asserted-by":"crossref","unstructured":"Manocha, S., Feinstein, D., Kumar, A. et al. (2002). Novel therapies for sepsis: antiendotoxin therapies. Expert Opinion on Investigational Drugs11, 1795\u2013812.","DOI":"10.1517\/13543784.11.12.1795"},{"key":"key\n\t\t\t\t20171010160019_R30","doi-asserted-by":"crossref","unstructured":"Sharma, V. K. & Dellinger, R. P. (2003). Recent developments in the treatment of sepsis. Expert Opinion on Investigational Drugs12, 139\u201352.","DOI":"10.1517\/13543784.12.2.139"},{"key":"key\n\t\t\t\t20171010160019_R31","doi-asserted-by":"crossref","unstructured":"Yethon, J. A. & Whitfield, C. (2001). Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria. Current Drug Targets. Infectious Disorders1, 91\u2013106.","DOI":"10.2174\/1568005014606143"},{"key":"key\n\t\t\t\t20171010160019_R32","unstructured":"Remick, D. G., Newcomb, D. E., Bolgos, G. L. et al. (2000). Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock13, 110\u20136."},{"key":"key\n\t\t\t\t20171010160019_R33","doi-asserted-by":"crossref","unstructured":"Tracey, K. J. & Abraham, E. (1999). From mouse to man: or what have we learned about cytokine-based anti-inflammatory therapies? Shock11, 224\u20135.","DOI":"10.1097\/00024382-199903000-00012"},{"key":"key\n\t\t\t\t20171010160019_R34","doi-asserted-by":"crossref","unstructured":"Ghiselli, R., Giacometti, A., Cirioni, O. et al. (2003). Neutralization of endotoxin in vitro and in vivo by Bac7(1-35), a proline-rich antibacterial peptide. Shock19, 577\u201381.","DOI":"10.1097\/01.shk.0000055236.26446.c9"},{"key":"key\n\t\t\t\t20171010160019_R35","doi-asserted-by":"crossref","unstructured":"Jaccard, C., Troillet, N., Harbarth, S. et al. (1998). Prospective randomized comparison of imipenem\u2013cilastatin and piperacillin\u2013tazobactam in nosocomial pneumonia or peritonitis. Antimicrobial Agents and Chemotherapy42, 2966\u201372.","DOI":"10.1128\/AAC.42.11.2966"},{"key":"key\n\t\t\t\t20171010160019_R36","doi-asserted-by":"crossref","unstructured":"Cohen, J. & McConnell, J. S. (1985). Antibiotic-induced endotoxin release. Lancetii, 1069\u201370.","DOI":"10.1016\/S0140-6736(85)90939-0"},{"key":"key\n\t\t\t\t20171010160019_R37","doi-asserted-by":"crossref","unstructured":"Prins, J. M., Kuijper, E. J., Mevissen, M. L. C. M. et al. (1995). Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infection and Immunity63, 2236\u201342.","DOI":"10.1128\/IAI.63.6.2236-2242.1995"},{"key":"key\n\t\t\t\t20171010160019_R38","doi-asserted-by":"crossref","unstructured":"Shenep, J. L., Barton, R. P. & Mogan, K. A. (1985). Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis. Journal of Infectious Diseases151, 1012\u20138.","DOI":"10.1093\/infdis\/151.6.1012"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/54\/3\/654\/2222843\/dkh390.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T04:12:29Z","timestamp":1682741549000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/54\/3\/654\/742033\/Therapeutic-efficacy-of-the-magainin-analogue"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,1]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2004,9]]},"published-print":{"date-parts":[[2004,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkh390","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2004,9]]},"published":{"date-parts":[[2004,9,1]]}}}